Publications by authors named "Patrice Beaudry"

Article Synopsis
  • Human prion diseases are severe neurodegenerative conditions with sporadic, infectious, and genetic forms, with the E200K mutation being a common genetic variant of Creutzfeldt-Jakob disease, which has no existing treatments.
  • Researchers created a genetic model using the nematode Caenorhabditis elegans to study the effects of the E200K prion protein mutation on neuronal health and behavior, revealing neurodegeneration and misfolding patterns.
  • This model helped identify five existing FDA-approved compounds that could combat the harmful effects of the E200K prion protein, advancing the research in prion disease therapies.
View Article and Find Full Text PDF

Prion diseases are characterized by the accumulation in the brain of a misfolded and protease-resistant form of the prion protein (PrP(c)). PrP(c) contains an amyloidogenic, neurotoxic sequence that is essential for conversion into PrP(Sc), the pathological isoform. During normal processing, PrP(c) is cleaved at a site within this sequence, and this cleavage is thought to destroy the amyloidogenic potential of the protein.

View Article and Find Full Text PDF

Systemic mastocytosis (SM) is characterized by proliferation of mast cells in various organs, which may release a wide variety of mediators, thereby explaining the broad clinical spectrum of disease manifestations. The potentially life-threatening systemic symptoms and tumoral proliferation are poorly controlled despite the use of several cytotoxic chemotherapies and/or symptomatic treatments. Twenty consecutive adult SM patients with histologically confirmed bone marrow (BM) involvement received interferon-alpha subcutaneously (1-5 million units/m2/d, with progressive dose intensification over the first month of treatment) and were evaluated after 6 months of therapy.

View Article and Find Full Text PDF